SEARCH

SEARCH BY CITATION

References

  • 1
    Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78: 285-291.
  • 2
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846-1850.
  • 3
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5: 632-634.
  • 4
    Kuderer NM, Francis CW, Culakova E, et al. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol. 2008; 26(May 20 suppl). Abstract 9521.
  • 5
    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484-3488.
  • 6
    ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997; 84: 1099-1103.
  • 7
    Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793-800.
  • 8
    Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110: 874-879.
  • 9
    Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 381S-453S.
  • 10
    Kearon C, Kahn SR, Agnelli G, Goldhaber SZ, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 454S-545S.
  • 11
    Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006; 25: 101-161.
  • 12
    National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease, version 2, 2008. Available at: http://www.nccn.org/professionals/physician_gls/default.asp. Accessed December 9, 2008.
  • 13
    Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25: 5490-5505.
  • 14
    Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2: 1266-1271.
  • 15
    Kakkar AK, Levine M, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcomes Study (FAMOUS). J Clin Oncol. 2004; 22: 1944-1948.
  • 16
    Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23: 2130-2135.
  • 17
    Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23: 2123-2129.
  • 18
    Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular weight heparin on cancer survival. J Thromb Haemost. 2007; 5: 729-737.
  • 19
    Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. Cancer. 2007; 110: 1149-1160.
  • 20
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160: 809-815.
  • 21
    Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest. 2009; 27: 105-115.
  • 22
    Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24: 484-490.
  • 23
    Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002; 4: 465-473.
  • 24
    Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006; 119: 60-68.
  • 25
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110: 2339-2346.
  • 26
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715-722.
  • 27
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-4907.
  • 28
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160: 761-768.
  • 29
    Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162: 1245-1248.
  • 30
    Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost. 2006; 95: 924-930.
  • 31
    El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis—A meta-analysis. Thromb Haemost. 2007; 97: 1031-1036.
  • 32
    Shah M, Ilson D, Kelsen D. Thromboembolic events in gastric cancer: high incidence in patients receiving ironotecan-and bevacizumab-based therapy. J Clin Oncol. 2005; 23: 2574-2576.
  • 33
    Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300: 2277-2285.
  • 34
    Deitcher SR, Gomes MPV. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004; 101: 439-449.
  • 35
    Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98: 708-714.
  • 36
    Khorana AA, Francis CW, Blumberg N, Culakova E, Refaal MA, Lyman GH. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med. 2008; 168: 2377-2381.
  • 37
    Kuderer NM, Khorana AA, Francis CW, et al. Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy [abstract]. Blood. 2008; 112: 71. Abstract 172.
  • 38
    Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost. 2007; 98: 656-661.
  • 39
    Burleigh E, Wang C, Foster D, et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm. 2006; 63( 20 suppl 6 ): S23-S29.
  • 40
    Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost. 2007; 5: 1610-1616.
  • 41
    Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003; 8: 381-388.
  • 42
    Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007; 119: 145-155.
  • 43
    Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346: 975-980.
  • 44
    Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007; 356: 1438-1444.
  • 45
    Falanga A, Lee AY, Streiff MB, Lyman GH. Cancer and thrombosis 3: anticoagulation in the treatment of venous thromboembolism in patients with cancer [abstract]. Am Soc Clin Oncol Ed Book. 2008; 2008: 258-268.
  • 46
    Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-153.
  • 47
    Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062-1072.
  • 48
    Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162: 1729-1735.
  • 49
    Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12: 389-396.
  • 50
    American Society of Clinical Oncology (ASCO). American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Available at: http://www.asco.org.
  • 51
    Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006; 81: 758-767.
  • 52
    Perry JR, Rogers L, Laperriere N, et al. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin in patients with newly diagnosed malignant glioma [abstract]. J Clin Oncol. 2007; 25: 18. Abstract 2011.
  • 53
    Agnelli G, Gussoni G, Bianchini C, Verso M, Tonato M. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: the PROTECHT study [abstract]. Blood. 2008; 112: 5. Abstract 6.
  • 54
    Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000; 160: 181-188.
  • 55
    Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008; 27: 1-10.
  • 56
    Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer. 1984; 53: 2046-2052.
  • 57
    Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med. 2004; 9: 205-213.
  • 58
    Cosgrove RH, Zacharski LR, Racine E, Andersen JC. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost. 2002; 28: 79-87.
  • 59
    Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160S-198S.
  • 60
    Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon. 2005; 51: 150-157.
  • 61
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 141S-159S.
  • 62
    Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med. 1998; 158: 1809-1812.
  • 63
    Engman CA, Zacharski LR. Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients. J Natl Compr Canc Netw. 2008; 6: 637-645.
  • 64
    Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases: the Heparin Prophylaxis Study Group. Lancet. 1996; 347: 1357-1361.
  • 65
    Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost. 2000; 83: 14-19.
  • 66
    American Society of Clinical Oncology. 2007 Clinical practice guideline recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Oncol Pract. 2007; 3: 326-329.
  • 67
    Lyman GH, Kuderer NM. Improving outcomes with prophylactic anticoagulation in patients with cancer: lessons from the American Society of Clinical Oncology Guidelines. In: KhoranaAA, FrancisCW, eds. Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment. New York, NY: Informa Healthcare USA, Inc.; 2008: 255-272.
  • 68
    Lyman GH. ASCO clinical practice guidelines and beyond. J Oncol Pract. 2007; 3: 330-331.
  • 69
    Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg. 1995; 82: 496-501.